The Moderna CEO's Bold Statement That May Mean Bad News for Novavax

Moderna (NASDAQ: MRNA) beat Novavax (NASDAQ: NVAX) to market with a coronavirus vaccine. The U.S. Food and Drug Administration (FDA) authorized Moderna's candidate in December. Novavax expects to report U.S. phase 3 trial data in the coming weeks and complete an Emergency Use Authorization (EUA) request this quarter.

But Novavax has a particular strength that makes it stand out in the sea of coronavirus vaccine developers. The company has an investigational flu vaccine that is only a step away from commercialization. And Novavax eventually aims to combine this candidate -- NanoFlu -- with its coronavirus vaccine candidate. Last week, though, Moderna's CEO Stephane Bancel said something that may jeopardize Novavax's chance to shine.

Image source: Getty Images.

Continue reading

Source Fool.com